<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p38" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_38{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_38{left:341px;bottom:30px;}
#t3_38{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_38{left:377px;bottom:30px;}
#t5_38{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_38{left:540px;bottom:30px;}
#t7_38{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_38{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_38{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_38{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_38{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_38{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_38{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_38{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_38{left:1105px;bottom:47px;letter-spacing:0.34px;}
#tg_38{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_38{left:1083px;bottom:85px;letter-spacing:-0.1px;}
#ti_38{left:356px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.23px;}
#tj_38{left:847px;bottom:786px;}
#tk_38{left:36px;bottom:755px;letter-spacing:-0.09px;}
#tl_38{left:36px;bottom:230px;}
#tm_38{left:46px;bottom:224px;letter-spacing:0.11px;word-spacing:0.01px;}
#tn_38{left:45px;bottom:208px;letter-spacing:0.08px;word-spacing:0.05px;}
#to_38{left:36px;bottom:199px;}
#tp_38{left:46px;bottom:193px;letter-spacing:0.13px;}
#tq_38{left:45px;bottom:178px;letter-spacing:0.11px;}
#tr_38{left:289px;bottom:178px;letter-spacing:0.07px;word-spacing:0.02px;}
#ts_38{left:518px;bottom:178px;letter-spacing:0.08px;}
#tt_38{left:36px;bottom:168px;}
#tu_38{left:45px;bottom:163px;letter-spacing:0.11px;word-spacing:0.01px;}
#tv_38{left:45px;bottom:147px;letter-spacing:0.1px;word-spacing:-0.02px;}
#tw_38{left:45px;bottom:132px;letter-spacing:0.11px;word-spacing:0.02px;}
#tx_38{left:36px;bottom:123px;}
#ty_38{left:46px;bottom:117px;letter-spacing:0.12px;}
#tz_38{left:45px;bottom:101px;letter-spacing:0.14px;}
#t10_38{left:43px;bottom:730px;letter-spacing:-0.1px;}
#t11_38{left:118px;bottom:737px;}
#t12_38{left:127px;bottom:730px;letter-spacing:-0.1px;}
#t13_38{left:43px;bottom:705px;letter-spacing:-0.1px;}
#t14_38{left:43px;bottom:689px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t15_38{left:54px;bottom:672px;letter-spacing:-0.13px;word-spacing:0.03px;}
#t16_38{left:302px;bottom:679px;}
#t17_38{left:43px;bottom:655px;letter-spacing:-0.09px;}
#t18_38{left:239px;bottom:655px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t19_38{left:54px;bottom:638px;letter-spacing:-0.13px;word-spacing:0.04px;}
#t1a_38{left:463px;bottom:646px;letter-spacing:-0.12px;}
#t1b_38{left:43px;bottom:615px;letter-spacing:-0.11px;}
#t1c_38{left:48px;bottom:594px;}
#t1d_38{left:65px;bottom:594px;letter-spacing:-0.09px;}
#t1e_38{left:172px;bottom:602px;}
#t1f_38{left:48px;bottom:578px;}
#t1g_38{left:65px;bottom:578px;letter-spacing:-0.09px;}
#t1h_38{left:311px;bottom:585px;}
#t1i_38{left:48px;bottom:561px;}
#t1j_38{left:65px;bottom:561px;letter-spacing:-0.09px;}
#t1k_38{left:65px;bottom:544px;letter-spacing:-0.08px;}
#t1l_38{left:304px;bottom:551px;}
#t1m_38{left:316px;bottom:544px;letter-spacing:-0.08px;}
#t1n_38{left:418px;bottom:551px;}
#t1o_38{left:43px;bottom:511px;letter-spacing:-0.1px;word-spacing:-0.13px;}
#t1p_38{left:43px;bottom:487px;letter-spacing:-0.1px;}
#t1q_38{left:43px;bottom:470px;}
#t1r_38{left:53px;bottom:470px;letter-spacing:-0.1px;word-spacing:0.02px;}
#t1s_38{left:355px;bottom:477px;letter-spacing:-0.12px;}
#t1t_38{left:43px;bottom:446px;letter-spacing:-0.11px;}
#t1u_38{left:43px;bottom:430px;}
#t1v_38{left:53px;bottom:430px;letter-spacing:-0.1px;word-spacing:0.02px;}
#t1w_38{left:376px;bottom:437px;letter-spacing:-0.14px;}
#t1x_38{left:43px;bottom:413px;}
#t1y_38{left:53px;bottom:413px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t1z_38{left:396px;bottom:420px;letter-spacing:-0.45px;}
#t20_38{left:43px;bottom:396px;}
#t21_38{left:53px;bottom:396px;letter-spacing:-0.13px;word-spacing:-0.01px;}
#t22_38{left:54px;bottom:379px;letter-spacing:-0.09px;}
#t23_38{left:155px;bottom:387px;letter-spacing:-0.14px;}
#t24_38{left:43px;bottom:355px;letter-spacing:-0.1px;}
#t25_38{left:43px;bottom:339px;letter-spacing:-0.08px;}
#t26_38{left:48px;bottom:322px;}
#t27_38{left:65px;bottom:322px;letter-spacing:-0.1px;word-spacing:0.02px;}
#t28_38{left:410px;bottom:329px;letter-spacing:-0.12px;}
#t29_38{left:43px;bottom:290px;letter-spacing:-0.1px;}
#t2a_38{left:43px;bottom:266px;letter-spacing:-0.08px;}
#t2b_38{left:54px;bottom:247px;letter-spacing:-0.08px;}
#t2c_38{left:400px;bottom:255px;letter-spacing:-0.13px;}
#t2d_38{left:648px;bottom:727px;letter-spacing:-0.09px;}
#t2e_38{left:648px;bottom:710px;letter-spacing:-0.09px;}
#t2f_38{left:648px;bottom:686px;letter-spacing:-0.1px;}
#t2g_38{left:648px;bottom:662px;letter-spacing:-0.08px;}
#t2h_38{left:718px;bottom:669px;}
#t2i_38{left:648px;bottom:645px;letter-spacing:-0.09px;}
#t2j_38{left:913px;bottom:653px;letter-spacing:-0.13px;}
#t2k_38{left:648px;bottom:627px;}
#t2l_38{left:659px;bottom:627px;letter-spacing:-0.08px;}
#t2m_38{left:1046px;bottom:634px;letter-spacing:-0.14px;}
#t2n_38{left:648px;bottom:608px;}
#t2o_38{left:659px;bottom:608px;letter-spacing:-0.09px;}
#t2p_38{left:659px;bottom:590px;letter-spacing:-0.1px;}
#t2q_38{left:741px;bottom:598px;letter-spacing:-0.12px;}
#t2r_38{left:648px;bottom:572px;letter-spacing:-0.1px;}
#t2s_38{left:648px;bottom:553px;}
#t2t_38{left:659px;bottom:553px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t2u_38{left:659px;bottom:535px;letter-spacing:-0.09px;}
#t2v_38{left:802px;bottom:543px;letter-spacing:-0.14px;}
#t2w_38{left:648px;bottom:511px;letter-spacing:-0.11px;}
#t2x_38{left:648px;bottom:483px;letter-spacing:-0.08px;}
#t2y_38{left:718px;bottom:491px;}
#t2z_38{left:648px;bottom:466px;letter-spacing:-0.09px;word-spacing:-0.14px;}
#t30_38{left:654px;bottom:450px;}
#t31_38{left:670px;bottom:450px;letter-spacing:-0.09px;}
#t32_38{left:777px;bottom:457px;letter-spacing:-0.13px;}
#t33_38{left:654px;bottom:433px;}
#t34_38{left:670px;bottom:433px;letter-spacing:-0.08px;}
#t35_38{left:670px;bottom:416px;letter-spacing:-0.09px;}
#t36_38{left:742px;bottom:423px;letter-spacing:-0.14px;}
#t37_38{left:762px;bottom:416px;letter-spacing:-0.08px;}
#t38_38{left:852px;bottom:423px;letter-spacing:-0.14px;}
#t39_38{left:654px;bottom:399px;}
#t3a_38{left:670px;bottom:399px;letter-spacing:-0.09px;}
#t3b_38{left:838px;bottom:407px;letter-spacing:-0.14px;}
#t3c_38{left:654px;bottom:382px;}
#t3d_38{left:670px;bottom:382px;letter-spacing:-0.09px;}
#t3e_38{left:852px;bottom:390px;}
#t3f_38{left:648px;bottom:359px;letter-spacing:-0.09px;word-spacing:-0.46px;}
#t3g_38{left:654px;bottom:342px;}
#t3h_38{left:670px;bottom:342px;letter-spacing:-0.08px;}
#t3i_38{left:735px;bottom:348px;letter-spacing:-0.13px;}
#t3j_38{left:654px;bottom:325px;}
#t3k_38{left:670px;bottom:325px;letter-spacing:-0.09px;}
#t3l_38{left:756px;bottom:332px;letter-spacing:-0.14px;}
#t3m_38{left:654px;bottom:308px;}
#t3n_38{left:670px;bottom:308px;letter-spacing:-0.08px;}
#t3o_38{left:742px;bottom:316px;letter-spacing:-0.14px;}
#t3p_38{left:654px;bottom:291px;}
#t3q_38{left:670px;bottom:291px;letter-spacing:-0.1px;}
#t3r_38{left:745px;bottom:299px;letter-spacing:-0.13px;}
#t3s_38{left:654px;bottom:275px;}
#t3t_38{left:670px;bottom:275px;letter-spacing:-0.11px;}
#t3u_38{left:708px;bottom:282px;letter-spacing:-0.14px;}
#t3v_38{left:654px;bottom:258px;}
#t3w_38{left:670px;bottom:258px;letter-spacing:-0.09px;}
#t3x_38{left:769px;bottom:265px;letter-spacing:-0.13px;}
#t3y_38{left:654px;bottom:241px;}
#t3z_38{left:670px;bottom:241px;letter-spacing:-0.1px;}
#t40_38{left:765px;bottom:248px;letter-spacing:-0.14px;}
#t41_38{left:654px;bottom:224px;}
#t42_38{left:670px;bottom:224px;letter-spacing:-0.09px;}
#t43_38{left:769px;bottom:232px;letter-spacing:-0.14px;}
#t44_38{left:928px;bottom:483px;letter-spacing:-0.1px;}
#t45_38{left:928px;bottom:466px;letter-spacing:-0.1px;}
#t46_38{left:933px;bottom:450px;}
#t47_38{left:950px;bottom:450px;letter-spacing:-0.08px;}
#t48_38{left:950px;bottom:433px;letter-spacing:-0.08px;}
#t49_38{left:950px;bottom:416px;letter-spacing:-0.08px;}
#t4a_38{left:950px;bottom:399px;letter-spacing:-0.09px;}
#t4b_38{left:1113px;bottom:407px;letter-spacing:-0.13px;}
#t4c_38{left:933px;bottom:382px;}
#t4d_38{left:950px;bottom:382px;letter-spacing:-0.09px;}
#t4e_38{left:950px;bottom:365px;letter-spacing:-0.08px;}
#t4f_38{left:950px;bottom:349px;letter-spacing:-0.08px;}
#t4g_38{left:950px;bottom:332px;letter-spacing:-0.09px;}
#t4h_38{left:1113px;bottom:339px;letter-spacing:-0.14px;}
#t4i_38{left:648px;bottom:200px;letter-spacing:-0.1px;}
#t4j_38{left:648px;bottom:174px;letter-spacing:-0.1px;}
#t4k_38{left:648px;bottom:156px;}
#t4l_38{left:659px;bottom:156px;letter-spacing:-0.09px;}
#t4m_38{left:659px;bottom:138px;letter-spacing:-0.09px;}
#t4n_38{left:763px;bottom:145px;letter-spacing:-0.14px;}
#t4o_38{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_38{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_38{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_38{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_38{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_38{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_38{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_38{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s7_38{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s8_38{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s9_38{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sa_38{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sb_38{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sc_38{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_38{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.se_38{font-size:14px;font-family:ArialMT_5tg;color:#000;}
.sf_38{font-size:17px;font-family:Webdings_k6;color:#000;}
.sg_38{font-size:17px;font-family:ArialMT_k0;color:#000;}
.sh_38{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts38" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg38Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg38" style="-webkit-user-select: none;"><object width="1210" height="935" data="38/38.svg" type="image/svg+xml" id="pdf38" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_38" class="t s0_38">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_38" class="t s1_38">® </span>
<span id="t3_38" class="t s0_38">(NCCN </span>
<span id="t4_38" class="t s1_38">® </span>
<span id="t5_38" class="t s0_38">), All rights reserved. NCCN Guidelines </span>
<span id="t6_38" class="t s1_38">® </span>
<span id="t7_38" class="t s0_38">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_38" class="t s2_38">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_38" class="t s2_38">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_38" class="t s3_38">NCCN Guidelines Version 4.2024 </span>
<span id="tb_38" class="t s3_38">Cancer of the Nasopharynx </span>
<span id="tc_38" class="t s4_38">NCCN Guidelines Index </span>
<span id="td_38" class="t s4_38">Table of Contents </span>
<span id="te_38" class="t s4_38">Discussion </span>
<span id="tf_38" class="t s5_38">NASO-B </span>
<span id="tg_38" class="t s5_38">1 OF 3 </span>
<span id="th_38" class="t s6_38">References </span>
<span id="ti_38" class="t s5_38">SYSTEMIC THERAPY FOR NASOPHARYNGEAL CANCERS </span>
<span id="tj_38" class="t s7_38">a </span>
<span id="tk_38" class="t s5_38">• The choice of systemic therapy should be individualized based on patient characteristics (eg, performance status [PS], goals of therapy). </span>
<span id="tl_38" class="t s8_38">a </span>
<span id="tm_38" class="t s9_38">The recommendations are based on clinical trial data for those with EBV-associated </span>
<span id="tn_38" class="t s9_38">nasopharynx cancer. </span>
<span id="to_38" class="t s8_38">b </span>
<span id="tp_38" class="t s9_38">The categories of evidence and consensus for induction therapy vary depending on </span>
<span id="tq_38" class="t s9_38">site (see disease-specific site in the </span><span id="tr_38" class="t sa_38">Head and Neck Table of Contents</span><span id="ts_38" class="t s9_38">). </span>
<span id="tt_38" class="t s8_38">c </span>
<span id="tu_38" class="t sb_38">Use of cisplatin + RT without adjuvant chemotherapy is a category 2B </span>
<span id="tv_38" class="t s9_38">recommendation for stage T3–4,N1–3,M0 or any T,N2–3,M0 disease; it is a category </span>
<span id="tw_38" class="t s9_38">2A recommendation for all other stages when indicated. </span>
<span id="tx_38" class="t s8_38">d </span>
<span id="ty_38" class="t s9_38">If not previously used, these regimens may be considered in subsequent-line therapy </span>
<span id="tz_38" class="t s9_38">as other recommended regimens. </span>
<span id="t10_38" class="t s5_38">Induction </span>
<span id="t11_38" class="t s7_38">b </span>
<span id="t12_38" class="t sc_38">/Sequential Systemic Therapy </span>
<span id="t13_38" class="t s5_38">Preferred Regimens </span>
<span id="t14_38" class="t sd_38">• Gemcitabine/cisplatin (category 1 for EBV-associated disease, category 2A </span>
<span id="t15_38" class="t sd_38">for non–EBV-associated disease) </span>
<span id="t16_38" class="t se_38">1 </span>
<span id="t17_38" class="t sd_38">• Docetaxel/cisplatin/5-FU </span><span id="t18_38" class="t sd_38">(dose-adjusted) (category 1 for EBV-associated </span>
<span id="t19_38" class="t sd_38">disease, category 2A for non–EBV-associated disease) </span>
<span id="t1a_38" class="t se_38">2-4 </span>
<span id="t1b_38" class="t s5_38">Other Recommended Regimens </span>
<span id="t1c_38" class="t sf_38"></span><span id="t1d_38" class="t sd_38">Cisplatin/5-FU </span>
<span id="t1e_38" class="t se_38">5 </span>
<span id="t1f_38" class="t sf_38"></span><span id="t1g_38" class="t sd_38">Docetaxel/cisplatin (category 2B) </span>
<span id="t1h_38" class="t se_38">6 </span>
<span id="t1i_38" class="t sf_38"></span><span id="t1j_38" class="t sd_38">Following induction, agents used with concurrent systemic therapy/RT </span>
<span id="t1k_38" class="t sd_38">typically include weekly cisplatin </span>
<span id="t1l_38" class="t se_38">7 </span>
<span id="t1m_38" class="t sd_38">or carboplatin </span>
<span id="t1n_38" class="t se_38">8 </span>
<span id="t1o_38" class="t s5_38">Systemic Therapy/RT Followed by Adjuvant Chemotherapy </span>
<span id="t1p_38" class="t s5_38">Preferred Regimens </span>
<span id="t1q_38" class="t sd_38">• </span><span id="t1r_38" class="t sg_38">Cisplatin + RT followed by cisplatin/5-FU </span>
<span id="t1s_38" class="t se_38">7,9 </span>
<span id="t1t_38" class="t s5_38">Other Recommended Regimens </span>
<span id="t1u_38" class="t sd_38">• </span><span id="t1v_38" class="t sg_38">Cisplatin + RT followed by carboplatin/5-FU </span>
<span id="t1w_38" class="t se_38">10 </span>
<span id="t1x_38" class="t sd_38">• </span><span id="t1y_38" class="t sg_38">Cisplatin + RT without adjuvant chemotherapy </span>
<span id="t1z_38" class="t se_38">c,11 </span>
<span id="t20_38" class="t sd_38">• </span><span id="t21_38" class="t sg_38">Cisplatin + RT followed by capecitabine (for T4,N1–3 or any T,N2–3) </span>
<span id="t22_38" class="t sd_38">(category 2B) </span>
<span id="t23_38" class="t se_38">12 </span>
<span id="t24_38" class="t s5_38">Useful in Certain Circumstances </span>
<span id="t25_38" class="t sd_38">• If cisplatin ineligible or intolerant, carboplatin may be used as an alternative: </span>
<span id="t26_38" class="t sf_38"></span><span id="t27_38" class="t sg_38">Carboplatin + RT followed by carboplatin/5-FU </span>
<span id="t28_38" class="t se_38">8,13 </span>
<span id="t29_38" class="t s5_38">Reirradiation + Concurrent Systemic Therapy </span>
<span id="t2a_38" class="t sd_38">• Platinum-based regimens (eg, cisplatin, or </span>
<span id="t2b_38" class="t sd_38">carboplatin only if cisplatin ineligible/intolerant) </span>
<span id="t2c_38" class="t se_38">14,15 </span>
<span id="t2d_38" class="t s5_38">Recurrent, Unresectable, Oligometastatic, or Metastatic Disease </span>
<span id="t2e_38" class="t s5_38">(with no surgery or RT option) </span>
<span id="t2f_38" class="t s5_38">Preferred Regimens </span>
<span id="t2g_38" class="t sd_38">First-Line </span>
<span id="t2h_38" class="t se_38">d </span>
<span id="t2i_38" class="t sd_38">• Cisplatin/gemcitabine (category 1) </span>
<span id="t2j_38" class="t se_38">16,17 </span>
<span id="t2k_38" class="t sd_38">• </span><span id="t2l_38" class="t sg_38">Cisplatin/gemcitabine + toripalimab-tpzi (category 1) </span>
<span id="t2m_38" class="t se_38">18 </span>
<span id="t2n_38" class="t sd_38">• </span><span id="t2o_38" class="t sg_38">Cisplatin/gemcitabine + other PD-1 inhibitor (eg, pembrolizumab or </span>
<span id="t2p_38" class="t sd_38">nivolumab) </span>
<span id="t2q_38" class="t se_38">18,19,20 </span>
<span id="t2r_38" class="t sd_38">Subsequent-Line </span>
<span id="t2s_38" class="t sd_38">• </span><span id="t2t_38" class="t sg_38">Toripalimab-tpzi (if disease progression on or after platinum- </span>
<span id="t2u_38" class="t sd_38">containing therapy) </span>
<span id="t2v_38" class="t se_38">21 </span>
<span id="t2w_38" class="t s5_38">Other Recommended Regimens </span>
<span id="t2x_38" class="t sd_38">First-Line </span>
<span id="t2y_38" class="t se_38">d </span>
<span id="t2z_38" class="t sd_38">• Combination Therapy </span>
<span id="t30_38" class="t sf_38"></span><span id="t31_38" class="t sd_38">Cisplatin/5-FU </span>
<span id="t32_38" class="t se_38">22,23 </span>
<span id="t33_38" class="t sf_38"></span><span id="t34_38" class="t sd_38">Cisplatin or carboplatin/ </span>
<span id="t35_38" class="t sd_38">docetaxel </span>
<span id="t36_38" class="t se_38">24 </span>
<span id="t37_38" class="t sd_38">or paclitaxel </span>
<span id="t38_38" class="t se_38">22 </span>
<span id="t39_38" class="t sf_38"></span><span id="t3a_38" class="t sd_38">Carboplatin/cetuximab </span>
<span id="t3b_38" class="t se_38">25 </span>
<span id="t3c_38" class="t sf_38"></span><span id="t3d_38" class="t sd_38">Gemcitabine/carboplatin </span>
<span id="t3e_38" class="t se_38">1 </span>
<span id="t3f_38" class="t sd_38">• Single Agents </span>
<span id="t3g_38" class="t sf_38"></span><span id="t3h_38" class="t sd_38">Cisplatin </span>
<span id="t3i_38" class="t se_38">26,27 </span>
<span id="t3j_38" class="t sf_38"></span><span id="t3k_38" class="t sd_38">Carboplatin </span>
<span id="t3l_38" class="t se_38">28 </span>
<span id="t3m_38" class="t sf_38"></span><span id="t3n_38" class="t sd_38">Paclitaxel </span>
<span id="t3o_38" class="t se_38">29 </span>
<span id="t3p_38" class="t sf_38"></span><span id="t3q_38" class="t sd_38">Docetaxel </span>
<span id="t3r_38" class="t se_38">30,31 </span>
<span id="t3s_38" class="t sf_38"></span><span id="t3t_38" class="t sd_38">5-FU </span>
<span id="t3u_38" class="t se_38">27 </span>
<span id="t3v_38" class="t sf_38"></span><span id="t3w_38" class="t sd_38">Methotrexate </span>
<span id="t3x_38" class="t se_38">23,32 </span>
<span id="t3y_38" class="t sf_38"></span><span id="t3z_38" class="t sd_38">Gemcitabine </span>
<span id="t40_38" class="t se_38">33 </span>
<span id="t41_38" class="t sf_38"></span><span id="t42_38" class="t sd_38">Capecitabine </span>
<span id="t43_38" class="t se_38">34 </span>
<span id="t44_38" class="t sd_38">Subsequent-Line </span>
<span id="t45_38" class="t sd_38">• Immunotherapy </span>
<span id="t46_38" class="t sf_38"></span><span id="t47_38" class="t sd_38">Nivolumab if previously </span>
<span id="t48_38" class="t sd_38">treated, recurrent or </span>
<span id="t49_38" class="t sg_38">metastatic non-keratinizing </span>
<span id="t4a_38" class="t sd_38">disease (category 2B) </span>
<span id="t4b_38" class="t se_38">35,36 </span>
<span id="t4c_38" class="t sf_38"></span><span id="t4d_38" class="t sg_38">Pembrolizumab if previously </span>
<span id="t4e_38" class="t sd_38">treated, PD-L1–positive, </span>
<span id="t4f_38" class="t sd_38">recurrent or metastatic </span>
<span id="t4g_38" class="t sd_38">disease (category 2B) </span>
<span id="t4h_38" class="t se_38">37 </span>
<span id="t4i_38" class="t s5_38">Useful in Certain Circumstances </span>
<span id="t4j_38" class="t sd_38">Subsequent-Line </span>
<span id="t4k_38" class="t sd_38">• </span><span id="t4l_38" class="t sg_38">Pembrolizumab (for tumor mutational burden-high [TMB-H] tumors </span>
<span id="t4m_38" class="t sg_38">[≥10 mut/Mb]) </span>
<span id="t4n_38" class="t se_38">36 </span>
<span id="t4o_38" class="t sh_38">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
